mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment by AHMET ÖZTÜRK (8077292)

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Testis tissue apoptosis post PM2.5 exposure. by Cao Wang (1500691)

Subjects:

Effects of H5 (20 and 40 mg/kg, p.o.), and diazepam (2.5 mg/kg, i.p.) in the Rota-rod test in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

Combination treatment decreased PI3K/Akt/mTOR pathways more efficiently than SLCP or BBR treatments alone. by Panchanan Maiti (1459852)

Cardamonin decreased the protein expression of lipogenic proteins. by Peiguang Niu (17044532)

miR-450a decreases TMEM182 by directly targeting 3'-UTR. by En-Wei Hsing (154990)

Machine Learning Model Performance Sorted by Decreasing MAE. by Renan N. D. Almeida (9265283)

Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study by Kelly Fellows Maxwell (6852752)

“…At 12 months, increases in HDL-C (mean change: +6.0 mg/dl; 95% CI: 0.3, 12.0; p = 0.049) and decreases in BMI (mean change: -2.6 kg/m²; 95% CI: -3.6, -2.5; p < 0.001), LDL-C (mean change: -10.4 mg/dl; 95% CI:-19.7, -1.2; p = 0.029), TG (mean change: -29.2 mg/dl; 95% CI: -44.3, -14.2; p = 0.001), TG to HDL-C ratio (mean change: -0.6; 95% CI: -1.0, -0.3; p = 0.002) and TC to HDL-C ratio (mean change:-0.6; 95% CI: -1.0, -0.3; p = 0.003) were observed compared to baseline. …”

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Treatment of NCI-H1975 cell-transplanted mice with erastin showed a tendency of sensitization to X-ray irradiation with a decrease in glutathione concentration. by Yuki Shibata (5094866)

General patient characteristics. by Ekaterina A. Bryushkova (13360122)

Subjects:

Individual dynamics of blood parameters. by Ekaterina A. Bryushkova (13360122)

Subjects:

Baseline clinical characteristics of patients. by Ekaterina A. Bryushkova (13360122)

Subjects:

Changes in CRP and LDH levels over time. by Ekaterina A. Bryushkova (13360122)

Subjects:

Minimal dataset. by Ekaterina A. Bryushkova (13360122)

Subjects:

The outcome timepoints and the mortality level of patients. by Ekaterina A. Bryushkova (13360122)

Subjects:

Positional cloning of <i>qNN1</i> on chromosome 16. by Xinxin Li (281237)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…Moreover, mouse models suggested that compound <b>20g</b> (1.5 mg/kg) could achieve roughly the same efficacy against ulcerative colitis compared with tofacitinib (10 mg/kg) and did not impair natural killer cells. …”